EFFECT OF ANTI-PD-1 THERAPY COMBINATION ON TEMOZOLOMIDE IN MOUSE GLIOBLASTOMA

被引：0

作者：

Park, Junseong ^{[1
]}

Kim, Chang Gon ^{[2
]}

Shim, Jin-Kyong ^{[3
]}

Lee, Jae Eun ^{[1
]}

Chang, Jong Hee ^{[2
]}

Shin, Eui-Cheol ^{[2
]}

Kang, Seok-Gu ^{[1
]}

机构：

[1] Yonsei Univ, Coll Med, Severance Hosp, Dept Neurosurg,Brain Tumor Ctr, Seoul, South Korea

[2] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Deajeon, South Korea

[3] Severance Hosp, Seoul, South Korea

来源：

NEURO-ONCOLOGY | 2017年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IMMU-16

引用

页码：116 / 116

页数：1

共 50 条

[21] Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
Zhu, Ping
Li, Shi -You
Ding, Jin
Fei, Zhou
Sun, Sheng-Nan
Zheng, Zhao -Hui
Wei, Ding
Jiang, Jun
Miao, Jin -Lin
Li, San-Zhong
Luo, Xing
Zhang, Kui
Wang, Bin
Zhang, Kun
Pu, Su
Wang, Qian -Ting
Zhang, Xin-Yue
Wen, Gao -Liu
Liu, Jun O.
August, John Thomas
Bian, Huijie
Chen, Zhi-Nan
He, You-Wen
[J]. JOURNAL OF PHARMACEUTICAL ANALYSIS, 2023, 13 (06) : 616 - 624
[22] EFFICACY OF CXCR6 BLOCKADE AS A POTENTIATOR OF ANTI-PD-1 THERAPY FOR THE TREATMENT OF GLIOBLASTOMA
Pant, Ayush
Saleh, Laura
Patel, Kisha
Medikonda, Ravi
Lim, Michael
[J]. NEURO-ONCOLOGY, 2020, 22 : 107 - 107
[23] Pneumonitis with anti-PD-1/PD-L1 therapy
Naidoo, J.
Cunningham, J.
Woo, K. M.
Hellmann, M. D.
Postow, M. A.
Drilon, A. E.
Chaft, J. E.
Lesokhin, A. M.
Segal, N. H.
Callahan, M. K.
Rudin, C. M.
Iyriboz, T.
Wolchok, J. D.
[J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S103 - S103
[24] Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1+anti-CTLA-4 therapy
Edwards, Jarem J.
da Silva, Ines Pires
Ferguson, Angela
Johansson, Peter
Conway, Jordan
Attrill, Grace
Saw, Robyn P. M.
Thompson, John F.
Menzies, Alexander M.
Palendira, Umaimainthan
Long, Georgina, V
Scolyer, Richard A.
Wilmott, James S.
[J]. CANCER RESEARCH, 2020, 80 (16)
[25] Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV
Mylvaganam, Geetha H.
Chea, Lynette S.
Tharp, Gregory K.
Hicks, Sakeenah
Velu, Vijayakumar
Iyer, Smita S.
Deleage, Claire
Estes, Jacob D.
Bosinger, Steven E.
Freeman, Gordon J.
Ahmed, Rafi
Amara, Rama R.
[J]. JCI INSIGHT, 2018, 3 (18)
[26] Combination effect of anti-PD-1 antibody and PDGFR inhibitor on mouse model of liver metastasis from colorectal cancer
Kadota, Hiroki
Yuge, Ryou
Takigawa, Hidehiko
Onishi, Kana
Otani, Rina
Kitadai, Yasuhiko
Tanaka, Shinji
[J]. CANCER SCIENCE, 2022, 113 : 1706 - 1706
[27] Prospect of combination of anti-PD-1/PD-L1 therapy and other therapeutics for treatment of lung cancer
WANG Lu-yao
YAO Rui-xue
XU Qian-qian
LIU Jia
[J]. 中国药理学与毒理学杂志, 2019, (10) : 888 - 888
[28] Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
Zhang, Chaoxu
Fan, Yibo
Che, Xiaofang
Zhang, Min
Li, Zhi
Li, Ce
Wang, Shuo
Wen, Ti
Hou, Kezuo
Shao, Xinye
Liu, Yunpeng
Qu, Xiujuan
[J]. FRONTIERS IN ONCOLOGY, 2020, 10
[29] Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.
Lian, Bin
Tian, Hui
Si, Lu
Chi, Zhihong
Sheng, Xinan
Wang, Xuan
Mao, Lili
Bai, Xue
Tang, Bixia
Yan, Xieqiao
Li, Siming
Zhou, Li
Wei, Xiaoting
Li, Juan
Li, Caili
Cui, Chuanliang
Guo, Jun
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao
Andrew X. Chen
Robyn D. Gartrell
Andrew M. Silverman
Luis Aparicio
Tim Chu
Darius Bordbar
David Shan
Jorge Samanamud
Aayushi Mahajan
Ioan Filip
Rose Orenbuch
Morgan Goetz
Jonathan T. Yamaguchi
Michael Cloney
Craig Horbinski
Rimas V. Lukas
Jeffrey Raizer
Ali I. Rae
Jinzhou Yuan
Peter Canoll
Jeffrey N. Bruce
Yvonne M. Saenger
Peter Sims
Fabio M. Iwamoto
Adam M. Sonabend
Raul Rabadan
[J]. Nature Medicine, 2019, 25 : 462 - 469

← 1 2 3 4 5 →